The Melanoma Research Alliance (MRA)recently awarded $2.25 million in grants to three teams of investigators based at institutions in Israel and the United States.

The Melanoma Research Alliance (MRA), the leading private funder of melanoma research, and the Saban Family Foundation, a charitable foundation focused on supporting medical, children’s and education programs in the United States and Israel, recently awarded $2.25 million in grants to three teams of investigators based at institutions in Israel and the United States. These awards will support research to improve the treatment of melanoma,…

Read more...

Le Mieux Cosmetics recently presented its popular Eye Wrinkle Corrector to guests of Dine With Derek

Le Mieux Cosmetics recently presented its popular Eye Wrinkle Corrector to guests of Dine With Derek. Hosted by celebrity fashion stylist and newly-appointed Style Director of Bella NYC Magazine, Derek Warburton, the pre-Fashion Week event took place at New York City Meatpacking District hotspot Manon and included a fashion show, cocktails, and dinner for stylish guests.

Read more...

Suneva Medical, Inc. recently announced that it has amended its existing licensing agreement with Histogen, Inc

Suneva Medical, Inc. recently announced that it has amended its existing licensing agreement with Histogen, Inc. Under the terms of the amended agreement, Suneva Medical is the exclusive licensee for the distribution of the Regenica® skin care line through the physician-dispensed channel in Europe, most of Asia, South America, Canada, Australia, and the Middle East.

Read more...

FDA recently announced that it had granted a first-ever approval of a combination treatment for melanoma

The United States Food and Drug Administration (FDA) recently announced that it had granted a first-ever approval of a combination treatment for melanoma, the most deadly type of skin cancer. The agency approved the combination of GlaxoSmithKline’s genetically-targeted dabrafenib (Tafinlar™) and trametinib (Mekinist™) for patients with metastatic or unresectable melanoma whose tumors possess either the BRAF V600E or V600K genetic mutations.

Read more...

Sente, Inc. recently announced that the company has entered into a strategic partnership with ZendyBeauty

Sente, Inc. recently announced that the company has entered into a strategic partnership with ZendyBeauty, the innovative online platform connecting patients with Board-Certified cosmetic dermatologists and plastic surgeons. Under this alliance, each new and existing doctor to join the ZendyBeauty network will receive Sente Dermal Repair Cream, the first and only skin care regimen to utilize low molecular weight heparan sulfate (HS).

Read more...